Sarcoidosis-Associated Pulmonary Hypertension

Area of Science:

• Pulmonology
• Cardiology
• Rheumatology

Background:

• Sarcoidosis-associated pulmonary hypertension (SAPH) is a severe complication of sarcoidosis.
• It significantly impacts patient morbidity and mortality.
• Prevalence is estimated between 3-20% of sarcoidosis patients, especially with advanced fibrotic lung disease.

Purpose of the Study:

• To review the current understanding of Sarcoidosis-associated pulmonary hypertension.
• To highlight diagnostic approaches and the importance of understanding underlying mechanisms for treatment.

Main Methods:

• Review of current literature and clinical guidelines.
• Discussion of diagnostic tools including echocardiography and right heart catheterization.
• Emphasis on the multifactorial nature of SAPH mechanisms.

Main Results:

• SAPH definition has been updated (mean pulmonary arterial pressure >20 mmHg).
• Right heart catheterization is the gold standard for diagnosis.
• Echocardiography is the primary non-invasive screening tool.
• Mechanisms of SAPH are complex and require further elucidation.

Conclusions:

• SAPH is a critical complication of sarcoidosis with significant mortality implications.
• Accurate diagnosis relies on a combination of non-invasive screening and invasive confirmation.
• Personalized treatment requires a thorough understanding of the specific underlying mechanisms in each patient.